Hello AAPS Community Members –
For the upcoming NAber working group next week on Tuesday, March 18th, we will discuss two topics that have been brought to the group courtesy of Bonnie Wu and Marie-Eve Poupart, both regarding the Bioanalytical Strategy for deployment of NAb assays across ADA positive samples for high prevalence ADA (Bonnie) as well as NAb deployment strategies for multi-domain molecules (Marie-Eve).
Both presenters will share a 1-2 slide prompt, after which the floor will be open to discussion, interpretation, and lessons learned across the wide range of experience for AAPS community members. If
Tuesday, March 18th, at 12:00 EST Agenda
- NAb Bioanalytical Strategy - Properly Addressing High Incidedence/Prevalance ADA
- NAb Bioanalytical Strategy - Addressing Multi-Domain molecules
For anyone considering joining the NAber Working Group or who would be interested in the specific March 18th discussion, please feel free to reach out and please contact @Lynn Kamen or @Weifeng Xu to learn more about the NAber Working Group.
------------------------------
Andrew Asberry
Director, Oncology Bioanalytical Strategy Lead
AstraZeneca, Plc
Gaithersburg MD
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------